Fig. 5

Inhibiting DNA-PK or ATM enhances oncolytic therapy in BALB/c nude models of NCI-H460 xenografts. a, b NCI-H460 xenografts were treated with vehicle, CV-B5/F (5 × 10⁶ TCID₅₀, intratumorally injection), NU7441 (10 mg/kg/day, intraperitoneally) or a combination. Blank, n = 5; Vehicle, n = 5; CV-B5/F, n = 5; NU7441, n = 5; NU7441 + CV-B5/F, n = 5. Tumor growth presented as the mean tumor volume ± SEM (a). Images of tumors from each group in (a) at the experimental endpoints (b). c, d NCI-H460 xenografts were treated with vehicle, CV-B5/F (5 × 10⁶ TCID50, intratumorally injection), KU60019 (10 mg/kg/day, intraperitoneally) or a combination. Blank, n = 5; Vehicle, n = 5; CV-B5/F, n = 5; KU60019, n = 5; KU60019 + CV-B5/F, n = 5. Tumor growth presented as the mean tumor volume ± SEM (c). Images of tumors from each group in (c) at the experimental endpoints (d). e–g Tumor tissues from B (e) or D (f) were evaluated through IHC for Ki-67 (a marker of proliferation), p-H2AX, cleaved-caspase-3, cleaved-PARP, p-JNK, CV-B5/F, HMGB1. One-way ANOVA was used to analyze data (n = 20). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, Scale bar, 100 μm